IRVINGTON, N.Y., July 3, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its board of directors has approved a one-for-ten reverse stock split of the Company’s common stock to become effective at 5 p.m., Eastern Time, July 9, 2014. The Company will file an amendment to its Certificate of Incorporation on that date as authorized by the stockholders at the Company’s annual meeting held on May 15, 2014. The Company’s common stock is expected to commence trading on a post-reverse stock split basis on July 10, 2014. The common stock will continue to trade under the symbol “MELA.”
Help employers find you! Check out all the jobs and post your resume.
